Table 5.
Logistic regression for 30-days outcome.
| Outcome at 30 days | Univariate | Multivariate | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic | N | Alive (N = 679)a | Dead (N = 151)a | ORb | 95% CIb | p-value | ORb | 95% CIb | p-value |
| ASAc score | 828 | ||||||||
| 1. Healthy | 92 (14%) | 11 (7.3%) | — | — | — | — | |||
| 2. Moderate organic disease | 260 (38%) | 44 (29%) | 1.42 | 0.72, 2.99 | 0.33 | 1.29 | 0.48, 3.69 | 0.62 | |
| 3. Severe organic disease | 308 (45%) | 90 (60%) | 2.44 | 1.30, 5.02 | 0.009 | 1.71 | 0.61, 5.17 | 0.32 | |
| 4. Life-threatening organic disease | 18 (2.7%) | 5 (3.3%) | 2.32 | 0.67, 7.26 | 0.16 | 0.92 | 0.16, 4.99 | 0.93 | |
| Living | 822 | ||||||||
| Home—without assistance | 529 (78%) | 93 (63%) | — | — | — | — | |||
| Home—with assistance | 110 (16%) | 37 (25%) | 1.91 | 1.23, 2.93 | 0.003 | 2.93 | 1.52, 5.71 | 0.001 | |
| Institutionalized | 35 (5.2%) | 16 (11%) | 2.60 | 1.35, 4.82 | 0.003 | 2.70 | 1.09, 6.53 | 0.029 | |
| Other | 1 (0.1%) | 1 (0.7%) | 5.69 | 0.22, 145 | 0.22 | 7.12 | 0.27, 192 | 0.18 | |
| High energy trauma | 812 | ||||||||
| No | 531 (79%) | 122 (85%) | — | — | — | — | |||
| Yes | 137 (21%) | 22 (15%) | 0.70 | 0.42, 1.12 | 0.15 | 0.91 | 0.42, 1.91 | 0.81 | |
| Rotterdam CT score | 830 | ||||||||
| 209 (31%) | 17 (11%) | — | — | — | — | ||||
| 3 | 388 (57%) | 43 (28%) | 1.36 | 0.77, 2.51 | 0.30 | 1.04 | 0.54, 2.05 | 0.92 | |
| 4 | 61 (9.0%) | 28 (19%) | 5.64 | 2.93, 11.2 | <0.001 | 1.81 | 0.77, 4.34 | 0.18 | |
| 5/6 | 21 (3.1%) | 63 (42%) | 36.9 | 18.8, 76.4 | <0.001 | 11.3 | 4.70, 28.3 | <0.001 | |
| HISSd | 829 | ||||||||
| Minimal/mild | 389 (57%) | 15 (9.9%) | — | — | — | — | |||
| Moderate | 209 (31%) | 38 (25%) | 4.72 | 2.59, 9.03 | <0.001 | 5.44 | 2.73, 11.4 | <0.001 | |
| Severe | 80 (12%) | 98 (65%) | 31.8 | 18.0, 59.6 | <0.001 | 25.7 | 12.0, 58.5 | <0.001 | |
| Multitrauma | 829 | ||||||||
| No | 417 (62%) | 87 (58%) | — | — | — | — | |||
| Yes | 261 (38%) | 64 (42%) | 1.18 | 0.82, 1.68 | 0.38 | 1.65 | 0.95, 2.86 | 0.073 | |
| Sex | 830 | ||||||||
| Female | 289 (43%) | 56 (37%) | — | — | — | — | |||
| Male | 390 (57%) | 95 (63%) | 1.26 | 0.88, 1.82 | 0.22 | 1.70 | 1.02, 2.87 | 0.043 | |
| Antithrombotic therapy | 830 | ||||||||
| Antithrombotic naive | 309 (46%) | 51 (34%) | — | — | — | — | |||
| Antiplatelet therapy (mono or dual) | 228 (34%) | 39 (26%) | 1.04 | 0.66, 1.62 | 0.88 | 1.10 | 0.57, 2.12 | 0.78 | |
| Anticoagulant therapy | 120 (18%) | 52 (34%) | 2.63 | 1.69, 4.08 | <0.001 | 1.60 | 0.80, 3.19 | 0.18 | |
| Antiplatelet + anticoagulant therapy | 22 (3.2%) | 9 (6.0%) | 2.48 | 1.03, 5.53 | 0.032 | 3.39 | 1.00, 10.7 | 0.041 | |
| Age at injury (years) | 830 | 75 (70, 83) | 79 (73, 86) | 1.05 | 1.02, 1.07 | <0.001 | 1.07 | 1.04, 1.11 | <0.001 |
a
Statistics presented: n (%); median (IQR).
b
OR, odds ratio, CI, confidence interval.
c
ASA score, The American Society of Anaestesiologists score.
d
HISS, head injury severity scale.